All > Graft Vs Host Disease

Exercise for Graft-Versus-Host Disease

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Graft-Versus-Host Disease+2 MoreExercise - Behavioral
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is to study if it's possible to do aerobic and resistance exercises for people with GVHD.

Eligible Conditions
  • Graft-Versus-Host Disease
  • Graft Versus Host Disease
  • Chronic Graft-versus-Host Disease

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
uhCG/EGF
1
Ruxolitinib
1
Activated PTCy-MILs

Study Objectives

1 Primary · 14 Secondary · Reporting Duration: Evaluated at week 1 at baseline and week 7 on treatment, and at week 13 post-treatment also at week 25 follow-up

12 weeks
Proportion of patients completing the exercise intervention sessions
Week 25
Body Composition
Cardiopulmonary Fitness
Glycemic control level
Muscular Strength
Patient reported outcomes - Anxiety and Depression
Fatigue
Patient reported outcomes - Function
Patient reported outcomes - Quality of Life
Patient reported outcomes - Sleep
Physical Fitness
Physical Function - 6 minute walk test
Physical Function - Handgrip Strength
Physical Function - Timed Up and Go
Physical function - Margaria Stair Climb

Trial Safety

Safety Progress

1 of 3

Similar Trials

1
uhCG/EGF
1
Ruxolitinib
1
Activated PTCy-MILs

Trial Design

2 Treatment Groups

Exercise Group
1 of 2
Attention control Group
1 of 2

Experimental Treatment

36 Total Participants · 2 Treatment Groups

Primary Treatment: Exercise · No Placebo Group · N/A

Exercise Group
Behavioral
Experimental Group · 1 Intervention: Exercise · Intervention Types: Behavioral
Attention control Group
Behavioral
Experimental Group · 1 Intervention: Attention control · Intervention Types: Behavioral
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Exercise
2016
Completed Phase 1
~760
Attention control
2013
Completed Phase 2
~2260

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: evaluated at week 1 at baseline and week 7 on treatment, and at week 13 post-treatment also at week 25 follow-up

Who is running the clinical trial?

Dana-Farber Cancer InstituteLead Sponsor
1,016 Previous Clinical Trials
393,780 Total Patients Enrolled
Christina Dieli-ConwrightPrincipal InvestigatorDana-Farber Cancer Institute
2 Previous Clinical Trials
131 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 8 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have received allogeneic stem cell transplant at Dana-Farber Cancer Institute.
You have a physician's clearance to participate in moderate-vigorous intensity exercise.
You are willing to travel to Dana-Farber Cancer Institute for necessary data collection.
You are able to understand the nature and purpose of the study and are willing to sign a written informed consent document.
You must speak English.
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top